The life history of 21 breast cancers.
Nik-Zainal S., Van Loo P., Wedge DC., Alexandrov LB., Greenman CD., Lau KW., Raine K., Jones D., Marshall J., Ramakrishna M., Shlien A., Cooke SL., Hinton J., Menzies A., Stebbings LA., Leroy C., Jia M., Rance R., Mudie LJ., Gamble SJ., Stephens PJ., McLaren S., Tarpey PS., Papaemmanuil E., Davies HR., Varela I., McBride DJ., Bignell GR., Leung K., Butler AP., Teague JW., Martin S., Jönsson G., Mariani O., Boyault S., Miron P., Fatima A., Langerød A., Aparicio SAJR., Tutt A., Sieuwerts AM., Borg Å., Thomas G., Salomon AV., Richardson AL., Børresen-Dale A-L., Futreal PA., Stratton MR., Campbell PJ., Breast Cancer Working Group of the International Cancer Genome Consortium None.
Cancer evolves dynamically as clonal expansions supersede one another driven by shifting selective pressures, mutational processes, and disrupted cancer genes. These processes mark the genome, such that a cancer's life history is encrypted in the somatic mutations present. We developed algorithms to decipher this narrative and applied them to 21 breast cancers. Mutational processes evolve across a cancer's lifespan, with many emerging late but contributing extensive genetic variation. Subclonal diversification is prominent, and most mutations are found in just a fraction of tumor cells. Every tumor has a dominant subclonal lineage, representing more than 50% of tumor cells. Minimal expansion of these subclones occurs until many hundreds to thousands of mutations have accumulated, implying the existence of long-lived, quiescent cell lineages capable of substantial proliferation upon acquisition of enabling genomic changes. Expansion of the dominant subclone to an appreciable mass may therefore represent the final rate-limiting step in a breast cancer's development, triggering diagnosis.